Person:

Sade-Feldman, Moshe

Loading...
Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Sade-Feldman

First Name

Moshe

Name

Sade-Feldman, Moshe

Search Results

Now showing 1 - 2 of 2
  • Publication

    Resistance to checkpoint blockade therapy through inactivation of antigen presentation

    (Nature Publishing Group UK, 2017) Sade-Feldman, Moshe; Jiao, Yunxin J.; Chen, Jonathan; Rooney, Michael S.; Barzily-Rokni, Michal; Eliane, Jean-Pierre; Bjorgaard, Stacey L.; Hammond, Marc R.; Vitzthum, Hans; Blackmon, Shauna M.; Frederick, Dennie T.; Hazar-Rethinam, Mehlika; Nadres, Brandon A.; Van Seventer, Emily E.; Shukla, Sachet A.; Yizhak, Keren; Ray, John P.; Rosebrock, Daniel; Livitz, Dimitri; Adalsteinsson, Viktor; Getz, Gad; Duncan, Lyn; Li, Bo; Corcoran, Ryan; Lawrence, Donald; Stemmer-Rachamimov, Anat; Boland, Genevieve; Landau, Dan A.; Flaherty, Keith; Sullivan, Ryan; Hacohen, Nir

    Treatment with immune checkpoint blockade (CPB) therapies often leads to prolonged responses in patients with metastatic melanoma, but the common mechanisms of primary and acquired resistance to these agents remain incompletely characterized and have yet to be validated in large cohorts. By analyzing longitudinal tumor biopsies from 17 metastatic melanoma patients treated with CPB therapies, we observed point mutations, deletions or loss of heterozygosity (LOH) in beta-2-microglobulin (B2M), an essential component of MHC class I antigen presentation, in 29.4% of patients with progressing disease. In two independent cohorts of melanoma patients treated with anti-CTLA4 and anti-PD1, respectively, we find that B2M LOH is enriched threefold in non-responders (~30%) compared to responders (~10%) and associated with poorer overall survival. Loss of both copies of B2M is found only in non-responders. B2M loss is likely a common mechanism of resistance to therapies targeting CTLA4 or PD1.

  • Publication

    A Unique Subset of Glycolytic Tumour-Propagating Cells Drives Squamous Cell Carcinoma

    (Springer Science and Business Media LLC, 2021-02-22) Choi, Jeeeun; Sebastian, Carlos; Ferrer, Christina M.; Lewis, Caroline A.; Sade-Feldman, Moshe; LaSalle, Thomas; Gonye, Anna; Gimenez-Cassina Lopez, Begona; Abdelmoula, Walid M.; Regan, Michael S.; Cetinbas, Murat; Pascual, Gloria; Wojtkiewicz, Gregory; Silveira, Giorgia G.; Boon, Ruben; Ross, Kenneth; Tirosh, Itay; Saladi, Srinivas V.; Ellisen, Leif; Sadreyev, Ruslan; Benitah, Salvador Aznar; Agar, Nathalie; Hacohen, Nir; Mostoslavsky, Raul